DOCSLIB.ORG

Toronto Forensic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Toronto Forensic Library Listing – 3,549 spectra This extensive library is one of the most widely-used collections of its kind for forensic scientists and investigators. The Toronto Forensic Library contains FT- IR spectra of illegal and legal drugs, drug precursors and reagents used to prepare them and other substances encountered in forensic analysis. The library consists of 3,549 spectra that were measured at the Forensic Laboratories of the Canadian Department of Health and Welfare in Toronto. The spectra are distributed by Thermo Electron Corporation under license from Canadian Patent and Development Limited. Similar compounds are grouped together. The four major divisions of substances are: organic (over 3,000 spectra) inorganic (over 180 spectra) natural and commercial products (over 120 spectra) Compounds within the organic substances division are arranged by major functional groups present, but some types of compounds (for example, steroids, alkaloids and heterocyclics) are in separate groups. The organization of compounds within these groups is by skeleton and functionality. Toronto Forensic Index Compound Name Index Compound Name 22 (+)-Limonene; (+)-p-Mentha-1,8-diene, 65 1,2-Dichloroethane; Ethylene dichloride 97% 64 1,2-Dichloroethane; Ethylene dichloride 26 (+)-a-Pinene; (+)-2,6,6- 328 1,2-Diethoxybenzene Trimethylbicyclo[3.1.1]hept-2-ene 340 1,2-Dimethoxy-3-(methylthio)benzene 374 (+)-b-Thujone; (+)-(1S,4S)-1-Isopropyl- 2991 1,2-Naphthoquinone-4-sulfonic acid, Na 4-methylbicyclo[3.1.0]hexan-3- salt 130 (-)-Carveol; (-)-p-Mentha-6,8-dien-2-ol 122 1,2-Propanediol; Propylene glycol 1233 (-)-Chlorephedrine .HCl 121 1,2-Propanediol; Propylene glycol 1236 (-)-Chlorpseudoephedrine .HCl 355 1,3,5-Trimethoxybenzene 23 (-)-Limonene; (-)-p-Mentha-1,8-diene, 2317 1,3,9-Trimethylxanthine 92% 1491 1,3-Acetonedicarboxylic acid; 3- 1195 (-)-Norpseudoephedrine .HCl; (-)-2- Oxoglutaric acid Amino-1-phenyl-1-propanol .HCl, th 329 1,3-Benzodioxole; 1,2- 1193 (-)-Norpseudoephedrine; (-)-2-Amino-1- Methylenedioxybenzene phenyl-1-propanol, threo- 587 1,3-Diaminopropane 1194 (-)-Norpseudoephedrine; (-)-2-Amino-1- 140 1,3-Dichloro-2-propanol phenyl-1-propanol, threo- 331 1,3-Diethoxybenzene 1212 (-)-Pseudoephedrine .HCl; (-)-(1S,2S)-2- 269 1,3-Dihydroxynaphthalene; 1,3- Amino-1-phenyl-1-propanol Naphthalenediol 27 (-)-b-Pinene; (1S)-(-)-6,6-Dimethyl-2- 341 1,3-Dimethoxy-2-(methylthio)benzene methylenebicyclo[3.1.1]heptane 330 1,3-Dimethoxybenzene 1546 (1,2-Cyclohexylenedinitrilo)tetraacetic 2858 1,3-Dinitrobenzene acid 398 1,3-Diphenylacetone 79 (2-Bromoethyl)benzene; Phenethyl 397 1,3-Diphenylacetone bromide 2164 1,3-Diphenylguanidine 399 (2-Fluorophenyl)acetone 753 1,3-Phenylenediamine 400 (4-Fluorophenyl)acetone 751 1,3-Phenylenediamine 1864 (Carboxymethyl)trimethylammonium 752 1,3-Phenylenediamine chloride hydrazide; Girard's Reagent 754 1,3-Phenylenediamine .2HCl 1863 (Carboxymethyl)trimethylammonium 1812 1,4-Diacetylhydroquinone; chloride hydrazide; Girard's Reagent Hydroquinone diacetate 503 (E)-Cinnamaldehyde 81 1,4-Dichlorobenzene 1569 (E)-Cinnamic acid; (E)-3- 336 1,4-Diethoxybenzene Phenylpropenoic acid 335 1,4-Diethoxybenzene 2542 (E)-Cinnamoylcocaine 353 1,4-Dimethoxy-2-(methylthio)benzene 2543 (E)-Cinnamoylcocaine 334 1,4-Dimethoxybenzene 1545 (Ethylenedinitrilo)tetraacetic acid, 333 1,4-Dimethoxybenzene dicalcium salt 229 1,4-Dioxane 1544 (Ethylenedinitrilo)tetraacetic acid, 761 1,4-Phenylenediamine disodium salt; Disodium EDTA 762 1,4-Phenylenediamine .2HCl 1543 (Ethylenedinitrilo)tetraacetic acid, 763 1,4-Phenylenediamine sulfate disodium salt; Disodium EDTA 492 1,8-Dihydroxyanthraquinone 1542 (Ethylenedinitrilo)tetraacetic acid; 777 1,8-Naphthalenediamine; 1,8- EDTA, Edetic acid Diaminonaphthalene 1541 (Ethylenedinitrilo)tetraacetic acid; 819 1-(1-(4- EDTA; Edetic acid Methylphenyl)cyclohexyl)piperidine 377 (R)-(+)-Pulegone; (R)-(+)-p-Menth- 820 1-(1-(4- 4(8)-en-3-one Methylphenyl)cyclohexyl)piperidine .H 378 (R)-(-)-Carvone 98%; (R)-(-)-p-Mentha- Cl 6,8-dien-2-one 1150 1-(1- 141 1,1,1-Trichloro-2-methyl-2-propanol (Phenylmethyl)cyclohexyl)piperidine 72 1,1,1-Trichloroethane 1151 1-(1- 71 1,1,1-Trichloroethane (Phenylmethyl)cyclohexyl)piperidine .H 1924 1,1,3,3-Tetramethyl-2-thiourea Cl 2742 1,10-Phenanthroline .H2O 637 1-(1-Cyclohexenyl)piperidine 688 1,2,3,4-Tetrahydroquinoline 821 1-(1-Phenylcyclohexyl)-3- 479 1,2,3-Indantrione methylpiperidine 357 1,2,4-Trimethoxy-5-propenylbenzene; 822 1-(1-Phenylcyclohexyl)-3- Asarone methylpiperidine 493 1,2-Diaminoanthroquinone (c) 2007 Thermo Fisher Scientific Inc. All rights reserved. Page 1 of 43 Toronto Forensic Index Compound Name Index Compound Name 823 1-(1-Phenylcyclohexyl)-3- 2881 1-Chloro-2,4-dinitrobenzene methylpiperidine .HCl 139 1-Chloro-2-propanol 825 1-(1-Phenylcyclohexyl)-4- 57 1-Chlorobutane; Butyl chloride methylpiperidine 56 1-Chlorobutane; Butyl chloride 824 1-(1-Phenylcyclohexyl)-4- 59 1-Chlorohexane; Hexyl chloride methylpiperidine 97 1-Decanol; Decyl alcohol 826 1-(1-Phenylcyclohexyl)-4- 617 1-Dimethylamino-2-propanol methylpiperidine .HCl 98 1-Dodecanol; Dodecyl alcohol 796 1-(1-Phenylcyclohexyl)methylamine 674 1-Ethylaminocyclohexanecarbonitrile 797 1-(1- 2955 1-Heptanesulfonic acid, Na salt Phenylcyclohexyl)methylamine .HCl 2954 1-Heptanesulfonic acid, Na salt 827 1-(1-Phenylcyclohexyl)morpholine 94 1-Heptanol 828 1-(1-Phenylcyclohexyl)morpholine .HCl 99 1-Hexadecanol; Cetyl alcohol 810 1-(1-Phenylcyclohexyl)pyrrolidine 2953 1-Hexanesulfonic acid, Na salt 811 1-(1-Phenylcyclohexyl)pyrrolidine .HCl 93 1-Hexanol; Hexyl alcohol, 98% 812 1-(1-Phenylcyclohexyl)pyrrolidine .HCl 1492 1-Methyl-1-cyclohexanecarboxylic acid 1130 1-(2,5-Dimethoxyphenyl)-2- 2651 1-Methyl-3-hydroxypyridinium bromide aminobutane 1255 1-Methyl-4-phenyl-1,2,3,6- 679 1-(2- tetrahydropyridine Methylpiperidino)cyclohexanecarbonitri 682 1-Morpholinocyclohexanecarbonitrile le 266 1-Naphthol 2207 1-(2-Thienyl)-2-aminopropane 1455 1-Naphthyl isocyanate 2208 1-(2-Thienyl)-2-aminopropane .HCl 772 1-Naphthylamine 2214 1-(2-Thienyl)-2-nitropropene 773 1-Naphthylamine .HCl; 1- 1131 1-(3,4-Methylenedioxyphenyl)-2- Aminonaphthylene .HCl aminobutane 2790 1-Nitrobutane 1132 1-(3,4-Methylenedioxyphenyl)-2- 2789 1-Nitropropane aminobutane .HCl 2796 1-Nitroso-2-naphthol 1147 1-(3,4-Methylenedioxyphenyl)-2- 100 1-Octadecanol; Stearyl alcohol aminopentane 2956 1-Octanesulfonic acid sodium salt 1146 1-(3,4-Methylenedioxyphenyl)-2- 96 1-Octanol; Capryl alcohol aminopentane 95 1-Octanol; Octyl alcohol 1128 1-(3-Methoxyphenyl)-2-aminobutane 2952 1-Pentanesulfonic acid, Na salt 1129 1-(3-Methoxyphenyl)-2- 92 1-Pentanol; Amyl alcohol aminobutane .HCl 2181 1-Phenyl-1,2-propanedione-2-oxime 680 1-(3- 279 1-Phenyl-1-propanol; a-Ethylbenzyl Methylpiperidino)cyclohexanecarbonitri alcohol le 2963 1-Phenyl-1-propanone, bisulfite addition 2209 1-(3-Thienyl)-2-aminopropane product 2213 1-(3-Thienyl)-2-nitropropene 434 1-Phenyl-1-propanone; Propiophenone, 1133 1-(4-Bromo-2,5-dimethoxyphenyl)-2- 98% aminobutane 43 1-Phenyl-1-propene; 1-Propenylbenzene 681 1-(4- 1120 1-Phenyl-2-(ethylamino)butane .HCl Methylpiperidino)cyclohexanecarbonitri 1119 1-Phenyl-2-(methylamino)butane .HCl le 1121 1-Phenyl-2-(propylamino)butane 403 1-(m-Methoxyphenyl)-2-propanone; m- 1122 1-Phenyl-2-(propylamino)butane .HCl Methoxyphenylacetone 1118 1-Phenyl-2-aminobutane .HCl 402 1-(o-Methoxyphenyl)-2-propanone; o- 410 1-Phenyl-2-butanone Methoxyphenylacetone 409 1-Phenyl-2-butanone 401 1-(o-Methoxyphenyl)-2-propanone; o- 1127 1-Phenyl-2-ethanolaminobutane .HCl Methoxyphenylacetone 1126 1-Phenyl-2-ethanolaminobutane; 2-(2- 405 1-(p-Methoxyphenyl)-2-propanone; p- Hydroxyethylamino)-1-phenylbutane Methoxyphenylacetone 314 1-Phenyl-2-propanol 404 1-(p-Methoxyphenyl)-2-propanone; p- 804 1-Phenyl-N- Methoxyphenylacetone propylcyclohexanamine .HCl; PPC .HCl 1450 1-Bromo-3-cyano-3,3-diphenylpropane; 45 1-Phenylcyclohexene 4-Bromo-2,2-diphenylbutyronitril 677 1-Piperidinocyclohexanecarbonitrile; 58 1-Bromobutane; Butyl bromide PCC 90 1-Butanol; Butyl alcohol 675 1-Pyrrolidinocyclohexanecarbonitrile 91 1-Butanol; Butyl alcohol (c) 2007 Thermo Fisher Scientific Inc. All rights reserved. Page 2 of 43 Toronto Forensic Index Compound Name Index Compound Name 2211 1-[1-(2- 1003 2,3-Dimethoxyamphetamine .HCl Thienyl)cyclohexyl]piperidine .HCl; 522 2,3-Dimethoxybenzaldehyde TCP .HCl 1599 2,3-Dimethoxybenzoic acid 2212 1-[1-(2- 291 2,3-Dimethoxybenzyl alcohol Thienyl)cyclohexyl]piperidine .HCl; 546 2,3-Dimethyl-4-methoxybenzaldehyde; TCP .HCl 2,3-Dimethyl-p-anisaldehyde 2210 1-[1-(2-Thienyl)cyclohexyl]piperidine; 304 2,3-Dimethyl-4-methoxybenzyl alcohol TCP 1000 2,3-Methylenedioxyamphetamine 2373 17-Methyltestosterone 1001 2,3-Methylenedioxyamphetamine .HCl; 2343 17a-Dihydroequilenin; Estra-1,3,5,7,9- 2,3-MDA .HCl pentraene-3,17a-diol 776 2,3-Naphthalenediamine; 2,3- 2351 17a-Epitestosterone; 17a- Diaminonaphthalene Hydroxyandrost-5-en-3-one 460 2,4'-Dibromoacetophenone; p- 2334 17a-Estradiol; Estra-1,3,5(10)-triene- Bromophenacyl bromide 3,17a-diol 2841 2,4,5-Trimethoxy-b-methyl-b- 2384 17a-Hydroxyprogesterone caproate; nitrostyrene 17a-Hydroxypregn-4-ene-3,20-dione h 2812 2,4,5-Trimethoxy-b-nitrostyrene 2344 17b-Dihydroequilenin; Estra-1,3,5,7,9- 1087 2,4,5-Trimethoxyamphetamine .HCl; pentraene-3,17b-diol 2,4,5-TMA .HCl 2341 17b-Dihydroequilin; Estra-1,3,5(10),7- 1088 2,4,5-Trimethoxyamphetamine .HCl; tetraene-3,17b-diol 2,4,5-TMA .HCl 231 18-Crown-6 1085 2,4,5-Trimethoxyamphetamine; 2,4,5- 473 2',4',5'-Trihydroxybutyrophenone TMA 2923 2',7'-Dichlorofluorescein
Recommended publications
  • CHAPTER 29 ORGANIC CHEMICALS VI 29-1 Notes 1

    CHAPTER 29 ORGANIC CHEMICALS VI 29-1 Notes 1

    )&f1y3X CHAPTER 29 ORGANIC CHEMICALS VI 29-1 Notes 1. Except where the context otherwise requires, the headings of this chapter apply only to: (a) Separate chemically defined organic compounds, whether or not containing impurities; (b) Mixtures of two or more isomers of the same organic compound (whether or not containing impurities), except mixtures of acyclic hydrocarbon isomers (other than stereoisomers), whether or not saturated (chapter 27); (c) The products of headings 2936 to 2939 or the sugar ethers and sugar esters, and their salts, of heading 2940, or the products of heading 2941, whether or not chemically defined; (d) Products mentioned in (a), (b) or (c) above dissolved in water; (e) Products mentioned in (a), (b) or (c) above dissolved in other solvents provided that the solution constitutes a normal and necessary method of putting up these products adopted solely for reasons of safety or for transport and that the solvent does not render the product particularly suitable for specific use rather than for general use; (f) The products mentioned in (a), (b), (c), (d) or (e) above with an added stabilizer (including an anticaking agent) necessary for their preservation or transport; (g) The products mentioned in (a), (b), (c), (d), (e) or (f) above with an added antidusting agent or a coloring or odoriferous substance added to facilitate their identification or for safety reasons, provided that the additions do not render the product particularly suitable for specific use rather than for general use; (h) The following products, diluted to standard strengths, for the production of azo dyes: diazonium salts, couplers used for these salts and diazotizable amines and their salts.
  • Minnesota Statutes 1979 Supplement

    Minnesota Statutes 1979 Supplement

    MINNESOTA STATUTES 1979 SUPPLEMENT 152.01 PROHIBITED DRUGS CHAPTER 152. PROHIBITED DRUGS Sec. 152.01 Definitions. 152.02 Schedules of controlled substances; admin­ istration of chapter. 152.01 Definitions. [For text of subds 1 to 8, see M.S.1978] Subd. 9. Marijuana. "Marijuana" means all parts of the plant of any species of the genus Cannabis, including all agronomical varieties, whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin, but shall not include the mature stalks of such plant, fiber from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mix­ ture, or preparation of such mature stalks, except the resin extracted therefrom, fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination. [For text of subds 10 to 17, see M.S.1978] [ 1979 c 157 s 1 ] 152.02 Schedules of controlled substances; administration of chapter. [For text of subd 1, see M.S.1978) Subd. 2. The following items are listed in Schedule I: (1) Any of the following substances, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the exis­ tence of such isomers, esters, ethers and salts is possible within the specific chemical des­ ignation: Acetylmethadol; Allylprodine; Alphacetylmethadol; Alphameprodine; Alpham- ethadol; Benzethidine; Betacetylmethadol; Betameprodine; Betamethadol; Betaprodine; Clonitazene; Dextromoramide; Dextrorphan; Diampromide; Diethyliambutene; Dime- noxadol; Dimepheptanol; Dimethyliambutene; Dioxaphetyl butyrate; Dipipanone; Ethylmethylthiambutene; Etonitazene; Etoxeridine; Furethidine; Hydroxypethidine; Ke- tobemidone; Levomoramide; Levophenacylmorphan; Morpheridine; Noracymethadol; Norlevorphanol; Normethadone; Norpipanone; Phenadoxone; Phenampromide; Pheno- morphan; Phenoperidine; Piritramide; Proheptazine; Properidine; Racemoramide; Tri­ meperidine.
  • Amplification of Oxidative Stress by a Dual Stimuli-Responsive Hybrid Drug

    Amplification of Oxidative Stress by a Dual Stimuli-Responsive Hybrid Drug

    ARTICLE Received 11 Jul 2014 | Accepted 12 Mar 2015 | Published 20 Apr 2015 DOI: 10.1038/ncomms7907 Amplification of oxidative stress by a dual stimuli-responsive hybrid drug enhances cancer cell death Joungyoun Noh1, Byeongsu Kwon2, Eunji Han2, Minhyung Park2, Wonseok Yang2, Wooram Cho2, Wooyoung Yoo2, Gilson Khang1,2 & Dongwon Lee1,2 Cancer cells, compared with normal cells, are under oxidative stress associated with the increased generation of reactive oxygen species (ROS) including H2O2 and are also susceptible to further ROS insults. Cancer cells adapt to oxidative stress by upregulating antioxidant systems such as glutathione to counteract the damaging effects of ROS. Therefore, the elevation of oxidative stress preferentially in cancer cells by depleting glutathione or generating ROS is a logical therapeutic strategy for the development of anticancer drugs. Here we report a dual stimuli-responsive hybrid anticancer drug QCA, which can be activated by H2O2 and acidic pH to release glutathione-scavenging quinone methide and ROS-generating cinnamaldehyde, respectively, in cancer cells. Quinone methide and cinnamaldehyde act in a synergistic manner to amplify oxidative stress, leading to preferential killing of cancer cells in vitro and in vivo. We therefore anticipate that QCA has promising potential as an anticancer therapeutic agent. 1 Department of Polymer Á Nano Science and Technology, Polymer Fusion Research Center, Chonbuk National University, Backje-daero 567, Jeonju 561-756, Korea. 2 Department of BIN Convergence Technology, Chonbuk National University, Backje-daero 567, Jeonju 561-756, Korea. Correspondence and requests for materials should be addressed to D.L. (email: [email protected]). NATURE COMMUNICATIONS | 6:6907 | DOI: 10.1038/ncomms7907 | www.nature.com/naturecommunications 1 & 2015 Macmillan Publishers Limited.
  • The National Drugs List

    The National Drugs List

    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts

    Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts

    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
  • Ricini Oleum

    Ricini Oleum

    PHARMACOGNOSY II PHAR306 6th Semester 5th Lecture Prof. Dr. Müberra Koşar Ass. Prof. Dr. Aybike Yektaoğlu Eastern Mediterranean University Faculty of Pharmacy Department of Pharmacognosy PHARMACEUTICAL FIXED OILS AND ANIMAL FATS FIXED OILS & ANIMAL FATS Amygdalae oleum • “Almond oil” • obtained by crushing of the seeds of two varieties Prunus dulcis var. dulcis or P. dulcis var. amara (Rosaceae) in the cold • Almond oil is obtained in the Mediterranean countries (Italy, France, Spain and North Africa) where its culture is obtained • The only difference between the two varieties is the cyanogenic glycoside content of the var. amara FIXED OILS&ANIMAL FATS Amygdalae oleum • seeds carries 40-55% fixed oil • the refined oil mainly contains oleic acid (62-86%), linoleic (20- 30%), palmitic (4-9%) • Amydalae oleum raffinatum (Almond oil, refined) (Eur.Pu.) • Amydalae oleum virginale (Almond oil, virgin) (Eur.Ph.) • major used in cosmetology and dermatology • used as a carrier in oily injectable preparations FIXED OILS&ANIMAL FATS Arachidis oleum • “Arachis oil, Peanut oil” – “Peanut butter” • Arachis hypogaea (Fabaceae) • cultivated in South America, China, India, Australia, and West Africa • due to various genotypes they vary in fatty acid content • the seeds are cold-pressed • they have similar properties as olive oil • most suitable oil for added for embedding purposes into other oils (e.g. olive oil) FIXED OILS&ANIMAL FATS Arachidis oleum - content • seeds carries 40-50% fixed oil • 50-65% oleic acid • 18-30% linoleic acid • 8-10% palmitic
  • MSM Cross Reference Antihistamine Decongestant 20100701 Final Posted

    MSM Cross Reference Antihistamine Decongestant 20100701 Final Posted

    MISSISSIPPI DIVISION OF MEDICAID Antihistamine/Decongestant Product and Active Ingredient Cross-Reference List The agents listed below are the antihistamine/decongestant drug products listed in the Mississippi Medicaid Preferred Drug List (PDL). This is a cross-reference between the drug product name and its active ingredients to reference the antihistamine/decongestant portion of the PDL. For more information concerning the PDL, including non- preferred agents, the OTC formulary, and other specifics, please visit our website at www.medicaid.ms.gov. List Effective 07/16/10 Therapeutic Class Active Ingredients Preferred Non-Preferred ANTIHISTAMINES - 1ST GENERATION BROMPHENIRAMINE MALEATE BPM BROMAX BROMPHENIRAMINE MALEATE J-TAN PD BROMSPIRO LODRANE 24 LOHIST 12HR VAZOL BROMPHENIRAMINE TANNATE BROMPHENIRAMINE TANNATE J-TAN P-TEX BROMPHENIRAMINE/DIPHENHYDRAM ALA-HIST CARBINOXAMINE MALEATE CARBINOXAMINE MALEATE PALGIC CHLORPHENIRAMINE MALEATE CHLORPHENIRAMINE MALEATE CPM 12 CHLORPHENIRAMINE TANNATE ED CHLORPED ED-CHLOR-TAN MYCI CHLOR-TAN MYCI CHLORPED PEDIAPHYL TANAHIST-PD CLEMASTINE FUMARATE CLEMASTINE FUMARATE CYPROHEPTADINE HCL CYPROHEPTADINE HCL DEXCHLORPHENIRAMINE MALEATE DEXCHLORPHENIRAMINE MALEATE DIPHENHYDRAMINE HCL ALLERGY MEDICINE ALLERGY RELIEF BANOPHEN BENADRYL BENADRYL ALLERGY CHILDREN'S ALLERGY CHILDREN'S COLD & ALLERGY COMPLETE ALLERGY DIPHEDRYL DIPHENDRYL DIPHENHIST DIPHENHYDRAMINE HCL DYTUSS GENAHIST HYDRAMINE MEDI-PHEDRYL PHARBEDRYL Q-DRYL QUENALIN SILADRYL SILPHEN DIPHENHYDRAMINE TANNATE DIPHENMAX DOXYLAMINE SUCCINATE
  • Theophylline-7-Acetic Acid

    Theophylline-7-Acetic Acid

    Theophylline-7-acetic acid sc-237085 Material Safety Data Sheet Hazard Alert Code Key: EXTREME HIGH MODERATE LOW Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME Theophylline-7-acetic acid STATEMENT OF HAZARDOUS NATURE CONSIDERED A HAZARDOUS SUBSTANCE ACCORDING TO OSHA 29 CFR 1910.1200. NFPA FLAMMABILITY1 HEALTH2 HAZARD INSTABILITY0 SUPPLIER Santa Cruz Biotechnology, Inc. 2145 Delaware Avenue Santa Cruz, California 95060 800.457.3801 or 831.457.3800 EMERGENCY ChemWatch Within the US & Canada: 877-715-9305 Outside the US & Canada: +800 2436 2255 (1-800-CHEMCALL) or call +613 9573 3112 SYNONYMS C9-H10-N4-O4, "purine-7-acetic acid, 1, 2, 3, 6-tetrahydro-1, 3-dimethyl-2, 6-dioxo-", acefylline, acephylline, 7-(carboxymethyl)theophylline, "1, 2, 3, 6-tetrahydro-1, 3-dimethyl-2, 6-dioxopurine-7-acetic acid", "7-theophyllineacetic acid", "7-theophyllinylacetic acid", alkaloid Section 2 - HAZARDS IDENTIFICATION CHEMWATCH HAZARD RATINGS Min Max Flammability: 1 Toxicity: 2 Body Contact: 2 Min/Nil=0 Low=1 Reactivity: 1 Moderate=2 High=3 Chronic: 2 Extreme=4 1 of 8 CANADIAN WHMIS SYMBOLS EMERGENCY OVERVIEW RISK Harmful if swallowed. Irritating to eyes, respiratory system and skin. POTENTIAL HEALTH EFFECTS ACUTE HEALTH EFFECTS SWALLOWED ! Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual. ! Xanthine derivatives may produce nausea, vomiting, anorexia, stomach pain, vomiting of blood and diarrhea. Protein in the urine, increased amounts of urine output, and increased excretion of renal tubular cells and red blood cells may also occur.
  • Programme & Abstracts

    Programme & Abstracts

    The 57th Annual Meeting of the International Association of Forensic Toxicologists. 2nd - 6th September 2019 BIRMINGHAM, UK The ICC Birmingham Broad Street, Birmingham B1 2EA Programme & Abstracts 1 Thank You to our Sponsors PlatinUm Gold Silver Bronze 2 3 Contents Welcome message 5 Committees 6 General information 7 iCC maps 8 exhibitors list 10 Exhibition Hall 11 Social Programme 14 opening Ceremony 15 Schedule 16 Oral Programme MONDAY 2 September 19 TUESDAY 3 September 21 THURSDAY 5 September 28 FRIDAY 6 September 35 vendor Seminars 42 Posters 46 oral abstracts 82 Poster abstracts 178 4 Welcome Message It is our great pleasure to welcome you to TIAFT Gala Dinner at the ICC on Friday evening. On the accompanying pages you will see a strong the UK for the 57th Annual Meeting of scientific agenda relevant to modern toxicology and we The International Association of Forensic thank all those who submitted an abstract and the Toxicologists Scientific Committees for making the scientific programme (TIAFT) between 2nd and 6th a success. Starting with a large Young Scientists September 2019. Symposium and Dr Yoo Memorial plenary lecture by Prof Tony Moffat on Monday, there are oral session topics in It has been decades since the Annual Meeting has taken Clinical & Post-Mortem Toxicology on Tuesday, place in the country where TIAFT was founded over 50 years Human Behaviour Toxicology & Drug-Facilitated Crime on ago. The meeting is supported by LTG (London Toxicology Thursday and Toxicology in Sport, New Innovations and Group) and the UKIAFT (UK & Ireland Association of Novel Research & Employment/Occupational Toxicology Forensic Toxicologists) and we thank all our exhibitors and on Friday.
  • Effect of Theophylline and Enprofylline on Bronchial Hyperresponsiveness

    Effect of Theophylline and Enprofylline on Bronchial Hyperresponsiveness

    Thorax: first published as 10.1136/thx.44.12.1022 on 1 December 1989. Downloaded from Thorax 1989;44:1022-1026 Effect of theophylline and enprofylline on bronchial hyperresponsiveness G H KOETER, J KRAAN, M BOORSMA, J H G JONKMAN, TH W VAN DER MARK From the Department ofPulmonology and Lung Function, University Hospital, Groningen; Pharma Bio Research, Assen; and Astra Pharmaceutica, Rijswijk, The Netherlands ABSTRACT The effect of increasing intravenous doses of theophylline and enprofylline, a new xanthine derivative, on bronchial responsiveness to methacholine was studied in eight asthmatic patients. Methacholine provocations were carried out on three days before and after increasing doses of theophylline, enprofylline, and placebo, a double blind study design being used. Methacholine responsiveness was determined as the provocative concentration of methacholine causing a fall of 20% in FEV, (PC20). The patients were characterised pharmacokinetically before the main study to provide an individual dosage scheme for each patient that would provide rapid steady state plasma concentration plateaus of 5, 10, and 15 mg/l for theophylline and 1 25, 2 5, and 3-75 mg/l for enprofylline. Dose increments in the main study were given at 90 minute intervals. FEV, showed a small progressive decrease after placebo; it remained high in relation to placebo after both drugs and this effect was dose related. Methacholine PC20 values decreased after placebo; mean values were (maximum difference 2-0 and 1 7 higher after theophylline and enprofylline than after placebo copyright. doubling doses of methacholine); the effect of both drugs was dose related. Thus enprofylline and theophylline when given intravenously cause a small dose related increase in FEV1 and methacholine PC20 when compared with placebo.
  • Cinnamaldehyde Induces Release of Cholecystokinin and Glucagon-Like

    Cinnamaldehyde Induces Release of Cholecystokinin and Glucagon-Like

    animals Article Cinnamaldehyde Induces Release of Cholecystokinin and Glucagon-Like Peptide 1 by Interacting with Transient Receptor Potential Ankyrin 1 in a Porcine Ex-Vivo Intestinal Segment Model Elout Van Liefferinge 1,* , Maximiliano Müller 2, Noémie Van Noten 1 , Jeroen Degroote 1 , Shahram Niknafs 2, Eugeni Roura 2 and Joris Michiels 1 1 Laboratory for Animal Nutrition and Animal Product Quality (LANUPRO), Department of Animal Sciences and Aquatic Ecology, Ghent University, 9000 Ghent, Belgium; [email protected] (N.V.N.); [email protected] (J.D.); [email protected] (J.M.) 2 Centre for Nutrition and Food Sciences, Queensland Alliance for Agriculture and Food Innovation, The University of Queensland, St. Lucia, QLD 4072, Australia; [email protected] (M.M.); [email protected] (S.N.); [email protected] (E.R.) * Correspondence: [email protected] Simple Summary: The gut is able to “sense” nutrients and release gut hormones to regulate diges- tive processes. Accordingly, various gastrointestinal cell types possess transient receptor potential channels, cation channels involved in somatosensation, thermoregulation and the sensing of pungent and spicy substances. Recent research shows that both channels are expressed in enteroendocrine Citation: Van Liefferinge, E.; Müller, M.; Van Noten, N.; Degroote, J.; cell types responsible for the release of gut peptide hormones such as Cholecystokinin (CCK) and Niknafs, S.; Roura, E.; Michiels, J. Glucagon-like Peptide-1 (GLP-1). A large array of herbal compounds, used in pig nutrition mostly for Cinnamaldehyde Induces Release of their antibacterial and antioxidant properties, are able to activate these channels. Cinnamaldehyde, Cholecystokinin and Glucagon-Like occurring in the bark of cinnamon trees, acts as an agonist of Transient Receptor Potential Ankyrin 1 Peptide 1 by Interacting with (TRPA1)-channel.
  • CONTROLLED SUBSTANCE, DRUG, DEVICE and COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun

    CONTROLLED SUBSTANCE, DRUG, DEVICE and COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun

    CONTROLLED SUBSTANCE, DRUG, DEVICE AND COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun. 23, 2011, P.L. 36, No. 7 Cl. 35 Session of 2011 No. 2011-7 SB 1006 AN ACT Amending the act of April 14, 1972 (P.L.233, No.64), entitled "An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for Schedule I controlled substances. The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows: Section 1. Section 4(1) of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, amended November 24, 1999 (P.L.894, No.55), is amended to read: Section 4. Schedules of Controlled Substances.--The following schedules include the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. (1) Schedule I--In determining that a substance comes within this schedule, the secretary shall find: a high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety for use under medical supervision. The following controlled substances are included in this schedule: (i) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation: 1.